“Biogen has been, and continues to be, committed to working with all stakeholders to ensure SPINRAZA is available as an option for people with SMA to treat this devastating disease,” said David Henderson, the managing director of Biogen Australia and New Zealand. …
Expanded funding of SPINRAZA for treatment of pre-symptomatic SMA babies
March 4, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Dimerix Phase 3 kidney trial clears seventh safety review
November 19, 2025 - - Australian Biotech -
Prescient secures EU orphan status for PTX-100 for cutaneous T-cell lymphomas
November 19, 2025 - - Australian Biotech -
BCAL advances early cancer detection portfolio as Australian launch looms
November 19, 2025 - - Australian Biotech -
Is this disconnect so entrenched we can no longer recognise the presence of a problem?
November 19, 2025 - - Latest News -
Minister managing the 'double-whammy' of participant and plan growth
November 19, 2025 - - Latest News -
Tryp advances psilocin trial for binge eating disorder as second patient enrolled
November 18, 2025 - - Australian Biotech -
Nyrada advances toward Phase 2a trial of cardioprotective candidate
November 18, 2025 - - Australian Biotech